Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Background: Guidelines advocate for including a Comprehensive Geriatric Assessment (CGA) in the evaluation of elderly bladder cancer (BC) patients. To date, CGAs have not been studied in clinical pHypotheses: Integrating a comprehensive Risk and Resilience (R2) assessment in shared decision-making for localized BC will decrease decisional conflict and anxiety/depression, while improving generic health-related quality of life (HRQOL) and satisfaction with cancer-care satisfaction at treatment selection. Additionally, the R2 assessment will alter physicians’ subjective risk assessment and decrease physician-reported decisional-conflict score (DCS). Aims: 1)To compare changes in patient-reported decisional conflict and health-related quality of life among localized BC patients who completed the R2 assessment with those undergoing the usual risk assessment.2)To test the impact of the R2 assessment on provider’s subjective assessment of a patient’s fitness for definitive treatment for BC and physician-reported DCS after treatment selection. Methodologies: We will perform a prospective observational cohort study. Following informed consent, patients will receive standard of care risk assessment for 3 months and will serve as controls. Following treatment selection, patients will complete the DCS, PHQ-4 (anxiety and depression), QLQ-C30 and QLQ-BLM30 (HRQOL), and satisfaction with cancer care assessments; physicians will complete the DCS and render a subjective assessment of patients’ fitness for treatment. Patients being seen in months 4-11 will receive the R2 assessment. Patients and physicians will complete the outcome surveys as per above. Patient and physician-reported outcome measures will be compared between usual care and intervention cohorts. Concordance between physician risk assessment with/without the R2 score will be measured. This project responds to the BCAN PSN knowledge gaps in decision-making before definitive treatment of muscle-invasive BC.
Similar projects All >
Sorted by: Start Date
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 271,698
2019 - 2021
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Murray Dale Krahn, Girish Satish Kulkarni, William Wai Lun Wong, George Andrew Tomlinson, Nathan Perlis, Wassim Kassouf, Peter Colin Black, Shabbir Muhammad Husayn Alibhai

USD 77,161
2018 - 2019
Project list item
Studying the Effect of PPARG Pathway Modulation on Tumor Immune Microenvironment in Muscle Invasive Bladder Cancer

Congressionally Directed Medical Research Programs to Shruti D Shah

USD 262,050
2017 - 2018



    1103 Clinical Sciences


    1112 Oncology and Carcinogenesis


    1117 Public Health and Health Services

  • RCDC

    Mental Health

  • RCDC


  • RCDC

    Behavioral and Social Science

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC


  • Health Research Areas


  • Broad Research Areas

    Health Services Research